Expanding Therapeutic Radionuclide Supply to Prevent the Next Major Bottleneck in Radiopharmaceutical Growth

• Addressing the widening gap between isotope demand and available production capacity as more radiopharmaceutical companies, clinical trials and commercial programmes compete for limited supply
• Understanding how long infrastructure lead times, nuclear regulatory barriers and environmental approval requirements constrain rapid expansion of reactor and accelerator capacity
• Evaluating how emerging radionuclides including Actinium, Lead, Terbium and Copper are reshaping supply complexity through distinct production, transport and regulatory requirements

Session Reserved for Bicycle therapeutics